GITNUX MARKETDATA REPORT 2024

Antibody Drug Conjugate Industry Statistics

The Antibody Drug Conjugate industry is expected to experience significant growth due to increasing investment in research and development, leading to a rise in approved ADC therapies and market expansion.

Last Updated: June 22, 2024

Written & Summarized by: Jannik Lindner

How we write

In this post, we will explore the dynamic landscape of the antibody-drug conjugate industry, where rapid growth and innovation are driving significant market expansion. With key statistics highlighting market size, revenue projections, dominant players, clinical trials, and regional trends, we will gain a comprehensive understanding of the current state and future prospects of ADCs.

Statistic 1

"The global antibody-drug conjugates market size was valued at USD 2.99 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 18.2% from 2021 to 2028."

Statistic 2

"Global Antibody Drug Conjugates (ADC) Market revenue is to reach a value of $3.2 Billion in 2026."

Statistic 3

"Within the antibiotic drug conjugate industry, Immunomedics Inc. accounted for about 55% of the total global antibody drug conjugates market in 2020."

Statistic 4

"By application, the breast cancer segment dominated the market with a value of over USD 1.48 billion in 2021 within the ADC industry."

Statistic 5

"The number of clinical trials conducted for ADCs approximately doubled from 97 in 2017 to 208 by 2020."

Statistic 6

"There are currently around 60 Antibody-Drug Conjugates (ADCs) in clinical trials worldwide."

Statistic 7

"US dominates the ADC market with more than 40% market share, closely followed by Europe and Asia-Pacific."

Statistic 8

"By the end of 2027, global Antibody Drug Conjugates (ADC) Drug market is to reach $10 Billion."

Statistic 9

"Seattle Genetics is working on 7 ADC projects, making it one of the top contributors to ADC research in the industry."

Statistic 10

"Predicted market value of ADCs in 2025 is estimated to be over 15 billion U.S. dollars."

Statistic 11

"Antibody-drug conjugate treatments generated around 1.6 billion U.S. dollars in 2019."

Statistic 12

"North America accounts for the highest revenue share in the ADC industry due to technological advancements and the high prevalence of cancer in the region."

Statistic 13

"The global ADC market had seized an opportunity of 3.9 Billion USD in the year 2020."

Statistic 14

"The FDA has approved 10 Antibody drug conjugates for marketing."

Statistic 15

"Approximately 45.4% of the companies have less than 5 ADCs in development."

Statistic 16

"Two antibody-drug conjugates, Trastuzumab deruxtecan and Belantamab mafodotin, received FDA approval in 2020."

Statistic 17

"As of 2021, around 89% of ADCs under development are linked to their respective payloads via cleavable linkers."

In conclusion, the antibody-drug conjugate industry is experiencing substantial growth, with the market size expected to more than triple from 2020 to 2028. Immunomedics Inc. emerges as a significant player in this market, particularly within the breast cancer segment. The increase in clinical trials and the rising number of ADC projects by key players like Seattle Genetics are indicative of the industry’s development and innovation. The dominance of the US in the ADC market underscores the importance of technological advancements and high cancer prevalence in driving revenue. With the FDA approval of several ADCs and the predicted market value surpassing billions of dollars, the future looks promising for the antibody-drug conjugate industry on a global scale.

Jannik Lindner

Jannik is the Co-Founder of Gitnux and has been working in the digital space since 2016. He is specialized in content and tech.

Can You Trust Our Report?

The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.

Learn more about our process here.